Histone Deacetylase Regulation of MAP Kinase Phosphatase-1 Acetylation and Inflammation (135.36)
Youngtae Jeong,Wangsen Cao,Charles Lowenstein
DOI: https://doi.org/10.4049/jimmunol.182.supp.135.36
2009-01-01
The Journal of Immunology
Abstract:Abstract The mitogen activated protein kinase (MAPK) pathway mediates Toll-like receptor signaling during innate immune responses. Histone deacetylases (HDACs) modulate inflammation by deacetylating histone and non-histone proteins. Previous studies in our lab identified MAP Kinase Phosphatase-1 (MKP-1) as a potential acetylation target. Thus, we hypothesize that HDACs regulate LPS-induced inflammation by deacetylating MKP-1. RAW264.7 mouse macrophages preferentially expressed HDAC1, 2, and 3 (class I HDAC isoforms). HDAC1, 2, and 3 interacted with MKP-1. To support our hypothesis, we adopted both genetic and pharmacologic approaches, using HDAC1, 2, and 3 siRNAs and MS-275, a HDAC1, 2, 3 specific inhibitor. Both silencing and pharmacologic inhibition of HDAC1, 2, and 3 increased MKP-1 acetylation in cells. HDAC1 decreased MKP-1 acetylation in vitro. Furthermore, both silencing and pharmacologic inhibition of HDAC1, 2, and 3 decreased LPS-induced p38 MAPK activation and iNOS expression. Finally, pharmacologic inhibition of HDAC1, 2, and 3 decreased LPS-induced NO and IL-6 production. Taken together, our results show that class I HDACs deacetylate MKP-1, and that this modification can significantly affect MAPK signaling and inflammation. Furthermore, our results suggest that MKP-1 is a potential therapeutic target in inflammatory diseases. Supported by the American Heart Association grant (0815093E).